Atopic Dermatitis
Early non-lesional filaggrin expression predicts childhood asthma in atopic dermatitis
WASHINGTON — Among children with atopic dermatitis, low non-lesional skin filaggrin expression during early ages predicted future asthma, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Daily tapinarof use leads to 75% improvements in Eczema Area and Severity Index scores
WASHINGTON — Treatment with 1% tapinarof cream led to symptom improvements for most patients with atopic dermatitis, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Top in allergy/asthma: FDA OKs Xolair; commercial sparks conversation about food allergies
The FDA has approved Xolair for the reduction of allergic reactions in children and adults with immunoglobulin E-mediated food allergy, according to a press release from Roche.
Pretreatment testing rates for patients with skin diseases may diverge from guidelines
Data showed that not all patients with chronic inflammatory skin diseases undergo pretreatment testing before initiating systemic immunomodulatory therapies, despite current guidelines, according to a study.
Plant-based topical successfully targets both inflammation, bacteria in atopic dermatitis
MIAMI BEACH, Fla. — Zabalafin, a nonsteroidal topical, demonstrated efficacy in reducing inflammation and bacteria on the skin of children and adults with atopic dermatitis, according to interim data presented in a poster at Masters of Pediatric Dermatology.
VIDEO: Topical treatments may be effective against moderate to severe atopic dermatitis
In this video, Raj Chovatiya, MD, PhD, discussed research into the OX40 inhibitor amlitelimab, as well as two topical medications, from the Maui Derm 2024 meeting, examining data into their use in treating atopic dermatitis.
VIDEO: Rocatinlimab shows long-term effects on atopic dermatitis
In this video, Raj Chovatiya, MD, PhD, discussed research into the OX40 inhibitor rocatinlimab from the Maui Derm 2024 meeting, examining data into its use in treating atopic dermatitis.
VIDEO: Ruxolitinib ‘pretty good’ long-term option for atopic dermatitis
In this video, Raj Chovatiya, MD, PhD, discussed research into the Janus kinase inhibitor ruxolitinib from the Maui Derm 2024 meeting, examining data into its use in treating atopic dermatitis.
VIDEO: Study probes lebrikizumab for atopic dermatitis patients with skin of color
In this video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-13 blocker lebrikizumab from the Maui Derm 2024 meeting, examining data into its use in treating atopic dermatitis.
Children, adolescents with difficult-to-control AD benefit from multidisciplinary approach
Children and adolescents with difficult-to-control atopic dermatitis can benefit from a multidisciplinary approach that combines the perspectives of dermatologists, allergists and family members, according to a study.